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Abstract: 
Goals of work: The goal of this study is to characterize sleep quality and quantity prior to and in the first three 
nights after initial chemotherapy for breast cancer.  
Materials and methods: This study makes use of secondary analysis of data from two separate randomized 
clinical trials (RCT) of behavioral interventions to improve fatigue and sleep. Patients came from two 
comprehensive cancer centers, three clinical cancer centers, and 10 community clinics in five states. 
Participants were women with stage I—IIIA breast cancer treated with anthracycline and/or cyclophosphamide-
based regimens. 
Main results: Baseline data from each RCT were used in the analysis. Sixty-five percent of women self-
reported poor sleep in the month preceding chemotherapy using the Pittsburgh Sleep Quality Index (PSQI) 
score >5. Three nights of actigraphy data indicated a wide range of sleep experience with an average of 10 
awakenings and time (minutes) awake after sleep onset (WASO-M) averaging 61 min per night. The first 
night's sleep was the worst. There was no statistically significant relationship between self-reported poor sleep 
and sleep measures obtained by actigraphy. Women with poor sleep at baseline (global PSQI >5) had 
significantly lower (p<0.001) physical (PCS) and mental (MCS) health status. However, neither the PCS nor 
MCS was associated with any of the average actigraphy sleep parameters or night 1 parameters in the 
aggregated sample. Increasing age was also associated with poorer sleep. 
Conclusions: A high percent of women with breast cancer begin chemotherapy with disturbed sleep and the 
initial nights after chemotherapy are characterized by sleep fragmentation that disrupts sleep maintenance. 
Interventions should focus on strategies to decrease the number and duration of night awakenings. Further 
research is needed to identify predictors of poor sleep during this time. 
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Article: 
Introduction 
Sleep–wake disturbances experienced by persons with cancer have received minimal attention from clinicians 
and researchers prior to the new millennium [1, 2]. Most estimates of the prevalence of various sleep–wake 
disturbances have been determined in cross-sectional surveys with mixed types of cancer, and range from 30% 
to 88% [3, 4]. Estimates in women with breast cancer have similar variability [5]. Although studies of sleep 
during treatment, post-treatment survivorship, and in women with metastatic disease have indicated problems 
such as difficulty falling asleep, frequent night-time awakenings, and increased daytime sleep, these studies are 
based on self-reports [6–10]. 
 
This report takes advantage of baseline data from two federally funded intervention trials to improve sleep and 
fatigue in order to characterize sleep quality and quantity prior to and in the first three nights after initial 
intravenous chemotherapy for breast cancer. The data sharing allows for analysis of both actigraphy and self-
reported sleep data in 183 women receiving intravenous chemotherapy for breast cancer. 
Review of literature 
One specific area in which there is limited knowledge about sleep–wake patterns is during the initial period 
after receiving intravenous chemotherapy treatment for breast cancer. A review of the literature found only four 
studies on sleep–wake patterns during the first few nights after the initial intravenous chemotherapy treatment 
for breast cancer (Table 1) [7, 8, 11–13]. Each study provides a limited picture of sleep immediately following 
chemotherapy. There is evidence to suggest that although sleep efficiency may average above the recommended 
85%, women experience problems with sleep maintenance, including increased number and duration of night 
awakenings; but data regarding total sleep time is conflicting. The number of night-time awakenings (average of 
eight to 10 per night) was above the normal adult experience of few and brief awakenings [14]. Time awake 
after sleep onset varied but was consistently more than the normal upper limit of 30 min/night. These data were 
all collected in small samples (n<75), reported limited sleep parameters, and did not consistently analyze for 
changes in the days following treatment. 
 
The studies to date also did not consider whether sleep changes are associated with baseline sleep quality status, 
baseline mental or physical health status, or demographic or clinical variables. Such associations might lead 
clinicians to target those at high risk for sleep problems. In addition, understanding patterns of sleep disturbance 
might begin to inform the influence of sleep on fatigue which is known to peak 48- to 72-h post-chemotherapy. 
Inconsistent with general population studies, evidence that links age to sleep–wake disturbances in cancer is 
inconsistent and no studies used actigraphy [3]. There is no evidence to date that indicates that a specific stage 
of breast cancer influences sleep. Studies that examined associations between physical performance or 
functional status and sleep in cancer patients have yielded inconsistent results [4]. In a study using actigraphy in 
24 patients receiving radiation therapy, there was a positive relationship between the Karnofsky performance 
status, sleep efficiency, and total sleep time [15]. No studies have specifically examined these relationships in 
women receiving initial chemotherapy for breast cancer. 
 
Therefore, the purposes of this report were to: 
 
1. Characterize sleep quality and quantity prior to and in the first three nights after initial intravenous chemo-
therapy for breast cancer; 
 
2. Examine sleep measures in relation to pre-chemotherapy reports of being a good or poor sleeper and self-
reported physical and mental well-being; and 
 
3. Evaluate whether sleep measures are associated with specific demographic (age, education) and clinical 
(stage of disease) variables. 
 
 
Materials and methods 
This study was a secondary analysis of data from two separate data sets. The analysis reported here was con-
ducted on the baseline data. Both studies were approved by appropriate institutional review boards and each 
participant signed an informed consent. Additional IRB approval was obtained to share de-identified data for 
purposes of this analysis. 
 
Design, setting, and sample of study 1 
Study 1 was a randomized clinical trial (RCT) designed to test the effect of an intervention to manage fatigue 
and insomnia during cancer therapy on fatigue, insomnia, and functional status. Individuals were included in the 
clinical trial if they were adults, 18 and over, initiating chemotherapy (CTX) with or without radiotherapy and 
any prior treatment, other than surgery, had been completed at least 1 month prior. The sample of the RCT 
consisted of 222 individuals treated for breast, lung, colorectal, advanced prostate, gynecologic or testicular 
cancer, or lymphoma. For this analysis, only the breast cancer subset (n=125) was included. Exclusions were 
made for treatment with stem cell transplantation or biotherapy, chronic fatigue syndrome, diagnosed sleep 
disorder of narcolepsy or sleep apnea, overt evidence of a psychiatric disorder, or initiation of treatment for 
anemia or depression during the past 3 weeks. 
 
Baseline questionnaires were completed prior to the initiation of chemotherapy and the delivery of the experi-
mental intervention focused on energy and sleep enhancement (n=64) or the control intervention consisting of 
information about a healthy diet (n=61). Baseline actigraph data were collected for three nights beginning on 
the first day of chemotherapy. 
 
Design, setting, and sample of study 2 
Study 2 was a randomized clinical trial of an intervention to manage fatigue by improving sleep during adjuvant 
breast cancer CTX. The primary aim was to test the effect of the sleep intervention on fatigue. Individuals were 
included in the clinical trial if they were initiating anthracycline-based CTX. The sample of the RCT consisted 
of 219 women. Eligible individuals included adults age 19 and older who received an initial diagnosis of stages 
I—IIIA breast cancer, had undergone surgery, and were scheduled to receive adjuvant anthracycline-based 
chemotherapy. They were required to have a Karnofsky score of 60 or higher. Exclusion criteria included co-
morbid conditions such as chronic fatigue syndrome, unstable congestive heart failure, chronic obstructive 
pulmonary disease, insulin-dependent diabetes, neuromuscular disease, sleep apnea, abnormal thyroid function, 
chronic steroid therapy, or working a job requiring rotating or permanent night shifts. 
 
Baseline questionnaires were completed prior to the first chemotherapy. Baseline actigraphy data and daily 
diaries were collected for two days prior to the first chemotherapy and continued for 7 days after the first 
chemotherapy treatment on all participants in study 2. The data used in the present analysis included actigraph 
data recorded for the first 3 days of the initial chemotherapy cycle. Participants in the experimental arm were 
coached 2 days prior to the first treatment to develop an individual sleep promotion plan (ISPP©). The control 
arm received equal time and attention with information about healthy eating. Because actigraphy data were 
collected after the initiation of intervention, only control subjects were included in this analysis. 
 
Measures 
In both studies, subjective and objective measures of sleep/ wake were obtained. Questionnaires were used to 
obtain information about self-reported physical and mental functioning. Objective data were obtained by wrist 
actigraphy (Ambulatory Monitoring, Ardsley, NY, USA). Demographic information was obtained from the 
participant and clinical data were abstracted from the medical record. 
 
Subjective sleep/wake 
The Pittsburgh Sleep Quality Index (PSQI) is a 19-item self-report questionnaire that measures subjective sleep 
quality during the past month [16, 17]. In this study the PSQI was used to describe quality of sleep prior to 
beginning chemotherapy. Responses to the items are grouped into seven components measuring sleep quality, 
sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleep medication use, and daytime 
dysfunction. The components are weighted equally on a 0-3 scale, with a global PSQI score ranging from 0 to 
21. Higher scores indicate more severe complaints and poorer sleep quality. Previous reports of internal 
consistency ranked from 0.77 to 0.83 [17]. In the present sample, Cronbach's alpha for the global PSQI was 
0.73. Evidence for construct validity has also been demonstrated. A global score above 5 demonstrated 
sensitivity of 89.6% and specificity of 86.5% in differentiating good from poor sleepers who were in good 
health otherwise. This cut-off has been widely applied in sleep research. A cut-off score of 8 was found to 
discriminate good and poor sleep quality in 102 breast cancer survivors whose mean time since diagnosis was 
approximately 2.5 years [6]. 
 
Objective sleep/wake 
Octagonal motionlogger actigraph devices (Ambulatory Monitoring, Ardsley, NY, USA) were used to quantify 
and record rest/activity cycles. Actigraphy offers a non-invasive method of objectively quantifying actual body 
movement over time [18]. The device resembles a wrist watch and was worn by each participant continuously 
on the non-dominant wrist. The actigraph was worn in their usual environment, whether at home, place of 
employment, or both. A diary was used to validate time in bed and time awake. 
 
Actigraphy provides an index of sleep/wake and activity/ rest in natural settings, and it is a valid addition to 
diary information about sleep [19]. Actigraphy is sensitive and precise compared to self-report [20, 21]. 
Actigraphy provides continuous direct measurement of movement and indirect measurement of sleep. In healthy 
adults, scores are obtained using algorithms that correlate at greater than 90% with polysomnography, the gold 
standard for cortical activity measures of wake and sleep stages [22]. Sleep latency, or time to fall asleep, has 
not been found to be accurate using actigraphy [23] and therefore has not been included in this report. 
 
We analyzed actigraphy data for up to 72 h beginning the morning of the day of the first chemotherapy 
treatment using a consistent approach. Days of the week varied among participants based on the day that 
chemotherapy was received. A systematic protocol was used to mark day and night for the analysis. Action 4 
analysis program (Copyright (c) 1988–2001; Ambulatory Monitoring) was used to analyze data in 1-min 
epochs. Six sleep/wake parameters were selected for analysis including: total time in bed, total sleep time, 
number of awakenings, and minutes and percent of time awake after sleep onset (WASO-M and WASO-P). The 
sixth parameter, sleep percent (%), time asleep after sleep onset, is the preferred parameter to use to report sleep 
efficiency when using actigraphy because the value does not include the less reliable parameter of latency [24]. 
 
Physical and mental health status 
The Medical Outcomes Study Health Survey (MOS-SF 12) was used in study 1 and the MOS-SF 36v2 was used 
in study 2. The SF-36 is a multi-purpose, short-form health survey with 36 questions that yields 
psychometrically based physical and mental health summary measures. Factor analytic studies have confirmed 
physical and mental health factors account for 80–85% of the reliable variance [25]. Published reliability 
statistics have exceeded the minimum standard of 0.70 recommended for measures used in group comparisons 
in more than 25 studies [26]; most have exceeded 0.80 [27, 28]. Reliability estimates for physical and mental 
summary scores usually exceed 0.90 [25]. In 1996, Version 2 was introduced, improving on the original 
dichotomous scaling by using five-level response scaling and increasing the sensitivity of the scale [27]. The 
MOSSF-12 was derived from items in the SF-36 [29]. Both scales compute component t-scores of physical 
health status (Physical Component Score—PCS) and mental health status (Mental Component Score—MCS) 
which are normed on a 0 to 100 scale. In a comparative study in a rheumatoid arthritis sample, correlations 
between the two versions were 0.94 for the PCS and 0.71 for the MCS [30]. Data also support equivalence of 
the two tools in patients with coronary artery disease [31]. Ware reported that the SF-12 achieved multiple R 
squares of 0.911 and 0.918 in prediction of the SF-36 PCS and the SF-36 MCS scores, respectively [29]. Thus 
these calculated, normed t-scores were deemed equivalent for this analysis. 
 
Demographic and clinical information 
Data were collected in each study at baseline using a study-specific questionnaire developed by each team. Data 
that were collected in a comparable manner in both studies included age, ethnic/racial background, marital 
status, education, and disease stage. 
 
 
Data analysis 
By combining the eligible participants, women with breast cancer from the two previously described studies, we 
identified 229 potential participants for the present study (n=125 from Study 1, n=104 from Study 2). We then 
systematically reviewed the samples to assure homogeneity before combining the samples for analysis. We 
examined actigraphy data for completeness and accuracy; 27 individuals were excluded due to having only one 
night of actigraphy data. We also evaluated the distribution of actigraphy sleep parameters; eight individuals 
were excluded due to extreme sleep parameter values. The first study included patients regardless of cancer 
stage. To assure equivalency, we dropped five advanced stage cancer participants from the Study 1 pool. 
Additionally, to equate chemotherapy regimens between the two studies, we decided to include only those 
receiving anthracycline and/ or cyclophosphamide-based regimens. We excluded six individuals from Study 1 
who received alternative regimens. This resulted in a total sample of n=183 for the present study. 
 
The two data sets were examined for equivalency across all major outcomes using the two one-sided test of 
equivalency [32, 33]. In this process, we constructed a confidence interval (CI) for the differences between two 
groups for key sleep parameters. We used team consensus to determine a CI around a delta (Δ) based on the 
concept of clinically important differences. We then computed a confidence interval for the actual Δ for the 
same measures, defined as (Δ±1.64σ) where σ is the pooled standard deviation of the two groups. Group 
differences and the confidence interval for each variable were examined to see if these differences fell within 
the confidence intervals proposed for each outcome. The results of these analyses were mixed and thus we 
proceeded conservatively, reporting both cohort data from each sample and aggregated data as appropriate. 
 
Data were analyzed using SPSS V. 15 (SPSS, Chicago, IL, USA). Analyses included summary statistics, 
Pearson correlations, and comparisons using t-tests and analysis of variance (ANOVA). Repeated measures 
ANOVA was used to evaluate change in actigraphy patterns over time. 
 
Results 
Sample characteristics 
The sample characteristics are summarized in Table 1. The sample included 183 women with breast cancer 
Stage I to III. There were no significant differences in age between the women in Study 1, age 28 to 75, and 
study 2, age 35 to 74. The women were predominantly Caucasian and almost 80% had at least some college 
education. Chi square analysis indicated that there were significant differences in clinical stage between the two 
samples (Chi square=6.74, p=0.03). Study 2 had more women with Stage I breast cancer and Study 1 had more 
women with Stage III. 
 
Subjective and objective sleep 
The first aim was to characterize sleep quality and quantity prior to and in the first three nights after initial 
intravenous chemotherapy for breast cancer. Sleep parameters during the last month were measured by the 
PSQI at baseline and are summarized in Tables 2 and 3 and described here. Using the standard cut-off of >5 on 
the global PSQI score, 65% of the women were classified as poor sleepers. Based on the overall sleep quality 
item of the PSQI (Item 6), about one fourth (25.7%) of the respondents reported "fairly bad" or "very bad" sleep 
quality at baseline. For total sleep time, 32.2% reported sleeping less than 6 h per night; 41.4% used sleeping 
medication during the past month; of which 21.5% were using sleeping medication three or more times per 
week. Almost half (44.9%) reported habitual sleep efficiency less than 85%. Almost two-thirds (63.3%) 
reported trouble waking up in the night. The most common sleep disturbances that occurred three or more times 
per week, based on PSQI individual items, were due to going to the bathroom, pain, and feeling too hot (see 
Table 3). Participants in Study 1 had higher PSQI component scores (except for sleep disturbances) than those 
in Study 2; the global PSQI score was significantly higher, 7.98 (Study 1) vs. 6.80 (Study 2) (p<0.05). 
 
Sleep parameters measured by actigraphy for each night are summarized in Table 4. Due to different patterns 
within the two samples, we have reported summary data for each sample as well as the aggregated sample. All 
sleep parameters were worse on the first night following chemotherapy. Results from RM ANOVA for the 
aggregated sample indicated that there was a significant change in a positive direction over time for total sleep 
time (p< 0.01) and number of awakenings (p<0.05). Analysis within each study sample revealed that this same 
pattern of improved total sleep time existed within the Study 2 sample; but the change over time within the 
Study 1 sample was non-significant. The number of awakenings in Study 2 was higher (11 vs. 10) on night 1 
and then declined in a fairly linear fashion. In Study 1, the number of awakenings averaged slightly above 10 on 
both night 1 and 2 and then declined on the third night. The range and standard deviation of both variables were 
quite large indicating individual variation. 
 
We also analyzed the actigraphy data averaged over two to three nights to describe the extent to which 
participants experienced sleep—wake changes that are indicative of poor sleep [34]. For the aggregated sample, 
26.8% had sleep percent that was below 85% although total sleep time was greater than 8 h for 48.6% of 
participants. Almost half of the sample (47%) had 10 or more awakening per night. 
 
Objective sleep parameters and baseline (pre-chemotherapy) sleep and health status 
The second aim was to examine differences in objective sleep parameters based on pre-chemotherapy self-
reports of being a good or poor sleeper. We also examined associations of self-reported physical and mental 
well-being with sleep measures (see Table 5). The actigraphy sleep parameters, averaged over two or three 
nights, were compared with independent t-tests based on the baseline global PSQI score, categorized as good 
(<5) or poor (>5) [16]. Using this categorization, it is notable that 65% of participants were categorized as poor 
sleepers. Analysis using an alternative cut-off of 8 [6] reduced the percent of poor sleepers to 35%. Although 
each actigraphy parameter (except average number of awakenings) in the poor sleeper group did reflect poorer 
sleep, the differences were not statistically significant (p>0.05) with either cut-off score. We have reported data 
using the widely accepted cut-off of >5.0. There were also no differences in actigraphy parameters based on 
whether or not pain or hot flashes were disturbing sleep three or more times per week (per PSQI) prior to 
beginning chemotherapy. 
 
Women with poor sleep at baseline (global PSQI >5) had significantly lower (p<0.001) physical (PCS) and 
mental (MCS) health status. The relationship between baseline health status as measured by the MOS-SF and 
the actigraphy sleep parameters were examined with Pearson correlations. Neither the PCS nor MCS were 
associated with any of the average actigraphy sleep parameters or night 1 parameters in the aggregated sample. 
The pattern of correlations varied between the study samples; all significant correlations were weak (<0.25). 
 
 
 
 
Demographic and clinical correlates 
The third aim was to examine associations between specific demographic (age, education) and clinical (stage of 
disease) variables with sleep measures. Pearson correlations were examined to determine whether there was an 
association between age and sleep parameters averaged across the three nights for the entire sample, and in the 
cohorts from each study (Table 6). 
 
Younger women’s sleep was of higher quality based on several sleep measures. In the entire sample, younger 
women spent more total time (minutes) in bed, had more total sleep time, and a higher sleep percent (p=0.02 to 
0.001). Younger age was also associated with more total sleep time in both cohorts (p=0.02–0.03). In the Study 
1 cohort only, older women had higher WASO-P, percent time awake (p<0.001). 
 
Educational level was divided into two groups: those with and without education beyond high school. Using t-
tests, no associations were found between education and sleep measures except more average sleep time in 
those with education beyond high school. Using one-way analysis of variance procedures, there were no 
differences in sleep variables based on stage of disease in either cohort or the aggregated sample. 
 
Discussion 
This report makes an important contribution to understanding the sleep experience in women initiating 
intravenous chemotherapy for breast cancer. Sharing two similar datasets provides a relatively large and robust 
sample to examine sleep/wake parameter and correlates. The sample far exceeds prior research in which sample 
sizes were mostly 25 or less. The sample is relatively homogeneous clinically as all women have limited stage 
breast cancer and are receiving chemotherapy with commonly used approaches—anthracycline and/or 
cyclophosphamide. Although some women were prescribed dose-dense regimens or those containing taxanes, 
this variability in treatment did not affect the first cycle. The sample is diverse in age but limited to 
predominantly Caucasian and well-educated women. Generalizability to a more racially and ethnically diverse 
population is thus limited. The samples differed statistically only on the distribution of disease stage, a factor 
that has not yet been strongly associated with sleep/wake disturbances. 
 
Plausible reasons for the differences in objective sleep parameters between samples 1 and 2 may relate to differ-
ences in pre-chemotherapy sedation, anti-emetic regimens, and use of sleeping medications. These variables 
were not measured in a detailed enough way in either study to allow comparisons and such detail will be 
important to include in future studies. Dexamethasone is commonly used in anti-emetic regimens and may have 
contributed to poorer sleep quality on the night after the chemotherapy was administered. Additionally, the 
incidence of uncontrolled nausea from the chemotherapy may have differed between the two samples. The 
PSQI showed that participants in study 1 made greater use of sleep medications prior to treatment; it is possible 
that this practice continued during cancer therapy. 
 
The results of the PSQI indicate that a high proportion of women begin chemotherapy with a history of poor 
sleep. Yet, the aggregated sample mean of 7.45 on the global PSQI score was somewhat lower than the 8.8 
previously reported by Berger [12]. Problems in maintaining sleep were predominant and the highest PSQI 
component score was for sleep disturbances. Common causes of sleep disturbance (that is going to the 
bathroom, pain, and being too hot) were similar to those reported by Fortner [35]. These results reinforce 
findings [36, 37] that most women experience disturbances in sleep/wake at the start of chemotherapy. The 
etiology of these sleep/wake disturbances may be due to the effects of cancer, stress, recent surgery, or mood 
disturbances such as anxiety-related anticipation of beginning chemotherapy [37]. This pattern also may be due 
to distress related to other symptoms or symptom clusters, such as the co-occurrence of pain, fatigue, or nausea. 
 
Analysis of sleep using actigraphy confirmed a pattern of disrupted sleep. The number of night-time 
awakenings (average of 10) was higher than normal [14, 34] and similar on average to those reported by Berger 
[12]. Sleep percent and WASO-M (an hour on average) are similar to reports in smaller samples [12, 13]. In 
spite of disrupted sleep, average time in bed exceeded 8 h and quantity of total sleep time averaged 7 to 8 h. 
These findings parallel those of Berger [12]who reported over 8 h of total rest, defined as total bed plus daytime 
naps minus sleep latency and WASO-M, but are higher than the study conducted by Payne in a Clinical 
Research Center where 11 women had a little over 6 h of sleep [13]. 
 
The study provided an opportunity to examine sleep parameters over three nights. There was a high degree of 
variance in most sleep parameters indicating a wide range of sleep experiences. Although there was a 
statistically significant change in selected sleep parameters over the three nights for the aggregated sample, the 
pattern varied between the two samples. Study 2 participants had worse sleep quality on the first night and thus 
a greater rate of improvement and a significant change over time. Similar patterns have not been described in 
previous research. The pattern also differs from Payne's report as the worst night of sleep in this sample was the 
first night after chemotherapy, while it was the second night in Payne's study [13]. Payne's subjects were not 
sleeping in their own home however [13]. The pattern reported in this study would be congruent with peaks in 
fatigue that occur 48- to 72-h post-treatment as poor sleep on nights 1 and 2 might contribute to increased 
fatigue [11, 38]. The degree of change in number of nighttime awakenings and WASO-M, though statistically 
significant, may not represent a clinically important change. The average night-time awakenings decreased to 
nine per night and WASO-M remained at 60 min, still indicating sleep disruption. 
 
There were no differences in actigraphy patterns over time between good and poor sleepers as identified by the 
pre-chemotherapy global PSQI cut-off scores of 5 and 8. These findings were surprising although this 
relationship has not been examined in similar samples of women with breast cancer. This finding supports other 
research that indicates that the commonly accepted subjective indicator of poor sleep quality (PSQI scores >5 or 
8) is measuring perceptions that complement, but are not consistently correlated with objective measures in 
either the general population [39] or in cancer patients [40]. It also might indicate that sleep disturbance after 
chemotherapy is similar regardless of self-reported sleep quality prior to treatment. 
 
There were significant differences in mental and physical health status based on good/poor sleeper status; poor 
sleepers had lower health status at baseline. The etiology of this relationship is unclear: does lower health status 
causes poor sleep or vice versa? In this sample, poorer health status was not related to the sleep parameters 
measured by actigraphy. This finding is in contrast to the relationship between sleep and performance status 
found by Miaskowski and Lee [15] in patients receiving radiation therapy. 
 
The associations found between the age and sleep measures were not surprising. There is solid evidence that 
sleep is more fragmented as we age, and that, in general sleep is of higher quality in younger women compared 
to older women [41-43]. The lack of association of educational level with sleep measures was not an 
unexpected finding as socioeconomic status has been found to have a more robust relationship with both 
subjective and objective sleep quality [44]. Women varied from stages I to III breast cancer. These stages 
represent localized disease so differences in sleep based on stage were not expected. A less extensive stage of 
breast cancer was associated with an increased risk for insomnia in a sample of 300 women who had been 
treated with radiotherapy for non-metastatic breast cancer [5]. Savard suggested a likely explanation for this 
finding was pre-existing sleep difficulties that were aggravated by cancer. 
 
Limitations 
The study was limited in that not all variables in two distinct studies could be matched, thus reducing the 
number of co-variates that could be included. SF-12 and SF-36 scores were compared. Literature supports such 
an approach but the items were not identical and this difference in measures may be one reason for differences 
in patterns of correlations. Actigraphy does not provide the best measure of sleep latency and thus this 
parameter is limited to self-report on the PSQI. The study 2 sample wore the actigraphy pre-chemotherapy and 
may have acclimated to wearing it by the time measurements used in this analysis were obtained. 
Generalizability to diverse racial or ethnic groups is limited. We also were unable to analyze for influences of 
pre-medications as well as specific chemotherapy regimens or doses. 
 
Implications 
Treatment of sleep/wake disturbance must begin with assessment prior to and during the treatment process. 
Interventions need to focus on improving sleep maintenance by decreasing the number of awakenings and 
reducing the time awake after each disruption. Specific strategies may include management of other symptoms 
such as fatigue, pain, or nausea; minimizing stimuli after awakening to use the bathroom; relaxation techniques; 
cognitive-behavioral therapy, and short-term pharmacologic therapy. Clearly, sleep/wake disturbance in this 
population may be complex and tailored approaches are warranted, especially given the high variability in sleep 
experience. 
 
Further research should try to better profile demographic and clinical risk factors to better characterize the 
predictors of sleep/wake disturbance during this period. Identifying patients at high risk for greater sleep/wake 
disturbances may allow for more targeted and effective interventions, thus allowing for better use of 
professional resources. Further study is needed to determine the cause of sleep disruption and to examine 
interventions to decrease the number and duration of sleep disturbances. More in-depth research of sleep latency 
is also needed. Research is also needed to evaluate interventions, such as the ones tested in Studies 1 and 2 in 
which nurse counselors provided a structured and multi-faceted cognitive-behavioral approach to enhancing 
sleep quality, as well as to better understand sleep patterns during the surgical recovery phase, throughout 
chemotherapy and through survivorship. 
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